Tyra Biosciences to Participate at September 2022 Investor Conferences

Tyra Biosciences (Nasdaq: TYRA), a precision oncology firm, announced its participation in key investor conferences.

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA), a precision oncology firm, announced its participation in key investor conferences. Management will present a pre-recorded session at H.C. Wainwright's 24th Annual Global Investment Conference from September 12-14, 2022, with the presentation available on September 12 at 7 AM ET. Additionally, Tyra will be featured at the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, with a panel discussion at 11:30 AM ET. Tyra is focused on therapies to overcome tumor resistance and is developing selective FGFR inhibitors.

Argus Session date unavailable

+8.24% session move Open Argus

Details

News Market Reaction – TYRA

The recorded move for TYRA in the trading session of this news was +8.24%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Sept. 8, 2022 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today announced that management will participate at the following investor conferences:

H.C. Wainwright's 24^th Annual Global Investment Conference

• September 12-14^th, 2022
• A pre-recorded presentation will be available here on September 12th at 7am ET

Cantor Oncology, Hematology & HemeOnc Conference

• September 28^th, 2022, in NY
• Panel discussion titled, "Resistant to Resistance: Approaches to Address Resistance in Oncology", on September 28th at 11:30am ET

About Tyra Biosciences

Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. TYRA's proprietary in-house discovery platform, SNÅP, enables the rapid and precise refinement of structural design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies.  Leveraging SNÅP, TYRA is developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR), which are altered in approximately 7% of all cancers.  TYRA-300 is an FGFR3 selective inhibitor for oncology.  TYRA-200 is an FGFR2 inhibitor that TYRA is developing initially in intrahepatic cholangiocarcinoma. TYRA is also targeting achondroplasia and other FGFR3-related skeletal dysplasias and FGFR4 and REarranged during Transfection kinase (RET) related cancers. TYRA is based in Carlsbad, CA.  For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn.

Contact:

Amy Conrad
aconrad@tyra.bio

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-at-september-2022-investor-conferences-301620833.html

SOURCE Tyra Biosciences, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What investor conferences will TYRA participate in September 2022?

Tyra Biosciences will participate in H.C. Wainwright's conference from September 12-14 and the Cantor Oncology conference on September 28.

When will Tyra's pre-recorded presentation be available?

The pre-recorded presentation will be available on September 12, 2022, at 7 AM ET.

What is the focus of Tyra Biosciences?

Tyra Biosciences focuses on developing therapies to overcome tumor resistance and improve cancer treatment outcomes.

What is the significance of the SNÅP platform for TYRA?

The SNÅP platform enables Tyra to rapidly refine therapies to address genetic alterations causing resistance in oncology.

What type of inhibitors is TYRA developing?

Tyra is developing selective inhibitors targeting Fibroblast Growth Factor Receptors (FGFR), particularly FGFR2 and FGFR3.